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Abstract
Background: Influenza viruses are among the major causes of serious human respiratory tract infection worldwide.
In line with the high disease burden attributable to influenza, these viruses play an important, but often neglected,
role in travel medicine. Guidelines and recommendations regarding prevention and management of influenza in
travellers are scarce. Of special interest for travel medicine are risk populations and also circumstances that facilitate
influenza virus transmission and spread, like travel by airplane or cruise ship and mass gatherings.
Methods: We conducted a PUBMED/MEDLINE search for a combination of the MeSH terms Influenza virus, travel,
mass gathering, large scale events and cruise ship. In addition we gathered guidelines and recommendations from
selected countries and regarding influenza prevention and management in travellers. By reviewing these search re-
sults in the light of published knowledge in the fields of influenza prevention and management, we present best
practice advice for the prevention and management of influenza in travel medicine.
Results: Seasonal influenza is among the most prevalent infectious diseases in travellers. Known host-associated
risk factors include extremes of age and being immune-compromised, while the most relevant environmental fac-
tors are associated with holiday cruises and mass gatherings.
Conclusions: Pre-travel advice should address influenza and its prevention for travellers, whenever appropriate on
the basis of the epidemiological situation concerned. Preventative measures should be strongly recommended for
travellers at high-risk for developing complications. In addition, seasonal influenza vaccination should be considered
for any traveller wishing to reduce the risk of incapacitation, particularly cruise ship crew and passengers, as well as
those participating in mass gatherings. Besides advice concerning preventive measures and vaccination, advice on
the use of antivirals may be considered for some travellers.
Key words: Travel medicine, influenza, vaccination, mass gatherings, seasonality
Introduction
Influenza viruses, members of the Orthomyxoviridae family, are
among the most diverse emerging infectious agents and cause
predominantly respiratory disease in humans. Of the three influ-
enza virus types (A, B and C), influenza A is the best known for
its ability to drift, re-assort and cause yearly seasonal outbreaks
in the temperate regions of the world. There are three presenta-
tions of human influenza: seasonal, avian and pandemic.
Seasonal influenza is caused by influenza A or B viruses and
affects 5–15% of the human population every year.1 Symptoms
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vary from mild respiratory complaints to fatal respiratory dis-
tress syndrome, while subclinical infections may also occur.
Severity of infection and outcome of disease depend largely on
the influenza virus involved and the immune and health status of
the infected individual. Most seasonal influenza virus infections
are self-limiting and patients do not need to seek medical care.
However, in most years, seasonal influenza does cause a consid-
erable burden of disease, especially in individuals at high-risk for
complications.2 Sporadic infections of humans with avian influ-
enza A viruses may occur causing serious and even fatal disease,
but these viruses are not efficiently transmitted among humans.
However, an avian virus that, by mutation and/or re-assortment,
acquires the capacity to be transmitted efficiently from human-
to-human, could be the basis of an emerging pandemic. Four ma-
jor influenza pandemics have occurred in the past century: in
1918–1920 (Spanish Flu), 1957–1958 (Asian Flu), 1968–1970
(Hong Kong Flu) and recently in 2009–2010 (Mexican or ‘swine’
Flu). Some avian strains pathogenic to humans may be directly
transmitted from birds to humans and may also adapt to human-
to-human transmissibility by mutation or re-assortment,3,4 avian
influenza viruses should be considered a major global health
threat.5
Several reviews have recently addressed influenza virus epi-
demiology, high-risk groups, vaccination strategies, and treat-
ments.6–10 However, one fast-growing risk group—travellers—
is largely missing from these overviews. Several changes in our
globalizing world contribute to the growing importance of this
group: (i) steady increase in total travel volume worldwide, (ii)
advent of mass-tourism and (iii) increasing numbers of immune-
compromised and elderly travellers. These changes highlight the
importance of harmonized international and national guidelines
for influenza prevention and treatment in travel medicine. For
example, it is easy to imagine how large pan-national religious
gatherings like the Hajj and Umrah, or international sporting
events and festivals could facilitate global spread of influenza.
Modern means of transport that gather large numbers of people
in relatively small spaces, like cruise ships and airplanes or air-
ports, may also require special attention from a public health
perspective. Herein, we summarize existing guidelines and dis-
cuss recommendations dealing with the prevention and manage-
ment of influenza from a traveller’s perspective including the
use of vaccines and antivirals as well as hygienic and societal
measures. Special attention is given to implications of air and
cruise-ship travel, travel to tropical regions and between hemi-
spheres, mass gatherings, necessary actions and directions for
future research.
Methods
A PUBMED/MEDLINE search was performed using a combina-
tion of the MeSH terms Influenza virus, travel, mass gathering,
cruise ships and large-scale events up to June 2016. Only articles
written in English were included. In addition, we gathered
guidelines and recommendations from selected countries and
public health organizations, associated with the International
Society of Travel Medicine with online accessible travel medi-
cine guidelines. Finally, we compared and evaluated these
search results in the light of currently published knowledge in
the fields of influenza prevention and management. PUBMED/
MEDLINE search resulted in 828 articles of which after screen-
ing for relevance by the authors 73 were included.
Results
Epidemiology of Seasonal Influenza in Travellers
Seasonal influenza is the most frequent vaccine preventable dis-
ease in travellers,11 with the risk of infection beginning upon
start of travel, i.e. gathering for transportation (i.e. busses,
trains and airports), when increased direct and indirect human-
to-human contacts take place. Influenza virus may be transmit-
ted by aerosol/droplet transmission, and through contact with
contaminated surfaces, like touching door handles and subse-
quently touching mucosal membranes.3 Most likely seasonal in-
fluenza viruses first replicate in the columnar epithelial cells of
the upper respiratory tract. From there the virus can spread
throughout the respiratory tract. Shedding of the seasonal
strains from the upper respiratory tract can be highly efficient
and virus can be readily recovered in respiratory secretions be-
fore symptom onset and for 5–8 days after the symptoms be-
come apparent.
Environmental Factors and Influenza Virus Infection Risk
during Travel
Among the challenging epidemiological aspects of seasonal in-
fluenza in travellers are differences in seasonality and virus
strains between climate zones and between northern and south-
ern hemispheres. In tropical areas, influenza viruses may circu-
late throughout the year with several seasonal peaks, whereas in
the moderate climate zones, circulation is largely limited to one
or two peaks in the fall and winter months.12 Recent data have
revealed interesting patterns of emergence and spread of anti-
genic drift variants, showing the global circulation of the differ-
ent seasonal influenza viruses. These observations have major
implications for selection of viruses that should be represented
in the seasonal vaccines, which from time to time results in dif-
ferent strains being represented in seasonal influenza vaccines
for the northern and southern hemispheres.13,14
Several studies have attempted to estimate the effectiveness
of influenza transmission during travel; especially air transpor-
tation. For instance, a study on four north American flights car-
rying ill passengers with confirmed pandemic H1N1 (2009)
infection calculated overall attack rates for acute respiratory in-
fection and influenza-like illness (ILI). In the 1–7 days following
travel, passenger attack rates were 5.2 and 2.4%, respectively,
of which a significant proportion were confirmed to be influ-
enza by serology.15 These results were in line with a retrospec-
tive study on in-flight transmission of pandemic H1N1 (2009)
infection in which 3% of exposed passengers developing ILI in
the days following the flight. Being placed in the same area (up
to two rows apart) as an index case with ILI, resulted in a signif-
icantly increased risk.16 Other studies using contact tracing,17
mathematical modelling and an experimental air cabin setting,
all confirmed the predisposing conditions of influenza droplet
transmission during flights.18–21
The increased risk of being infected with seasonal influenza ap-
pears not to be limited to the period directly before and during the
actual flight, but continues after leaving the aircraft. Several stud-
ies have shown high incidence rates of confirmed infection with
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seasonal influenza viruses during travel with the most recent anal-
ysis documenting a rate of 8.9 (95% CI 7.1–10.9) per 100 person-
months.11,12 However, only 10% had ILI. Among Dutch long-
term travellers, the influenza attack rate of serologically confirmed
infection during travel was 15%, and of symptomatic infection
was 6.3% (fever alone) and 2% (ILI), respectively.23 Results from
a GeoSentinel Surveillance Network study showed that persons
who travel to East and Southeast Asia have a 7-fold higher risk of
acquiring influenza compared with those who travel to other des-
tinations.24 Influenza virus infection in travellers largely occurs
outside the epidemic season in the country of departure, and espe-
cially at risk are those visiting family and relatives or those staying
abroad for >30 days.22,23,25 GeoSentinel and EuroTravNet act as
surveillance networks that monitor all travel-related illnesses re-
ported to any of their clinics worldwide. Data collected from these
organisations indicate that in 2008, prior to the H1N1 pandemic,
the number of influenza confirmed cases was at just 0.1%. During
2009, however the number of confirmed influenza cases rose to
prevalence figures of 11, 12, 18 and as high as 32% with the ma-
jority of these attributable to pH1N1.24,26–28 Close human-to-
human contact may also occur at mass-gatherings or on board
cruise ships, as discussed below.
Host Factors
High morbidity and mortality in influenza are seen especially
among those at the extremes of age (elderly and very young),
those with underlying health conditions and pregnant women.29
Underlying health conditions especially associated with an
increased risk for complicated influenza are immune-
compromised individuals, either due to the underlying disease,
or to immunomodulatory treatment, like organ transplant recip-
ients and those taking medication for autoimmune conditions.30
Furthermore, chronic pulmonary disease31, diabetes mellitus,
cardiovascular disease and malignancies are also considered risk
factors for developing severe influenza or complications.32
Impact on Travellers
Even a relatively mild, self-limiting seasonal influenza virus
infection can have drastic impact on the success of a holiday or
business trip. Furthermore, travel of athletes to international
contests and artists to performances abroad or social gatherings
like weddings can be ruined by influenza. Among the well-
recognized examples spread through the media are the German
national football team and coach during the 2010 World Cup in
South Africa and a famous rock star of a concert that had to be
cancelled as he got influenza.33–35
A large study of influenza virus infection in persons travel-
ling to tropical and sub-tropical countries found that 1.1% of
the travellers enrolled in the study seroconverted and that 40%
of those who seroconverted had sought medical attention during
their travel: a highly significant number.25 Influenza virus infec-
tions were acquired largely from Asia (47.5%), Africa (27.5%)
and Latin America (25%).25
It is important to note that, independent of travel, seasonal in-
fluenza outbreaks have been repeatedly associated with poor out-
comes even in patients without co-morbidities: including small
numbers who develop severe and even lethal influenza as well as
life-threatening complications. Examples include patients with se-
vere viral pneumonia, acute respiratory distress syndrome
(ARDS), post-influenza Staphylococcus aureus infection with a
potential Methicillin-resistant S. aureus infection or rare exam-
ples of myocarditis and encephalitis.32,36,37 It is now generally
accepted that even healthy individuals have a low but important
risk of developing severe influenza-associated disease.2
Furthermore, there is a significant economic burden of seasonal
influenza due to sick leave, medical care and medication.
Unexpected medical events while travelling can be particularly
expensive.
Preventive Measures and Treatment Options
There are several ways to decrease the risk of catching influenza.
First of all hygienic measures, including active ventilation of
crowded places, hand sanitation and (possibly) wearing a face-
mask can reduce the risk of spreading influenza. Influenza pre-
vention by vaccination and specific problems associated with
vaccinating travellers against influenza, are discussed in more in
detail below. As an adjunct to vaccination, the value of early anti-
viral therapy or prophylactic antiviral usage is also discussed.
Hygienic Measures
Several studies have addressed the effectiveness of non-
pharmaceutical interventions (NPIs) in reducing influenza virus
spread, especially in the case of a pandemic. For seasonal influ-
enza, most attention has been focused on hand hygiene and the
use of facemasks. These NPI’s may be especially important
when someone in the immediate environment or a travel com-
panion is infected.38 For instance, careful hand hygiene and the
use of facemasks appear to reduce household transmission of in-
fluenza virus when implemented within 36 h of symptom onset
of the index patient.39 The general utility of hand hygiene and
facemasks in reducing influenza spread has been confirmed by a
recent meta-analysis40 although the quality of the data in many
studies, particularly when children are involved, is relatively
poor.41 Furthermore, in studies that focus on scenarios in which
there is active, on-going influenza transmission in the popula-
tion, like during a pandemic, large variation in effectiveness of
these NPIs has been observed. Despite these limitations, there
seems to be sufficient evidence to conclude that facemasks, hand
hygiene and reduced crowding are effective in reducing the
spread of influenza.42 Hand hygiene would be relatively simple
for travellers to implement and several studies suggest that the
use of alcohol based sanitizers and hand washing after touching
contaminated surfaces can be effective.43,44
However, these trials were not conducted in travellers.
Facemask usage in travellers is particularly controversial and may
only have measurable impact when a close companion (i.e. shared
living quarters) is infected.45 In mass gatherings, there seems to be
a (very) modest decrease in risk of infection in persons using face-
masks.46 Furthermore, the overall effectiveness of masks and res-
pirators is likely dependent on consistent and correct usage.47 In
this light, it is important to note that up to 40% of influenza cases
may be transmitted prior to the onset of symptoms.48
Antiviral Options for Travellers
Another potential preventive strategy for influenza is the use of
antivirals either prophylactically or for early treatment.
Currently, the most effective anti-influenza drugs are the
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neuraminidase inhibitors (NIs: oseltamivir, zanamivir and
peramivir).49 M2 inhibitors (amantadine and rimantadine) are
rarely used since they suffer from rapid development of virus re-
sistance and virtually all currently circulating seasonal influenza
A viruses have pre-existing resistance.50 Furthermore, M2 inhib-
itors do have considerable side effects and are not effective
against influenza B viruses. Although influenza viruses can de-
velop resistance to individual NIs quite rapidly, the risk of resis-
tance development to the whole class of drugs is unlikely and
lower than with M2 inhibitors, illustrated by the fact that virtu-
ally no cross resistance to oseltamivir and zanamivir has been
identified.51 For travellers, the NIs may play a role in both pre-
and post-exposure prophylaxis, with confirming data coming
from both animal models (mouse and ferret) and human trials.52
NIs provide protective efficacy when used preventively in an
outbreak situation, or soon after the first clinical symptoms,
by reducing the duration and severity of symptomatic influ-
enza.53,54 Furthermore, several 2009 pandemic period observa-
tional studies suggest that early treatment can reduce rates of
hospitalisation and in-hospital mortality.55 Some consider the
use of NIs controversial because almost all published studies
have been industry-funded, and the reported effects are gener-
ally minor and there have been no large randomized control tri-
als proving efficacy for post-exposure treatment.53,54 However,
a recent independent meta-analysis showed that oseltamivir in
adults with influenza accelerates clinical symptom alleviation,
reduces risk of lower respiratory tract complications, and ad-
mission to hospital, while increasing the occurrence of nausea
and vomiting.56
Although NIs have relatively mild side effects, their cost and
modest efficacy suggest they should play only a limited role in rou-
tine pre-travel advice. However, elderly or other high-risk groups
in which vaccine efficacy can be low, could be advised to consider
bringing a NI for influenza early treatment, if access to medical
care at the destination will be limited. Especially since in many
countries NI requires a medical script to be purchased and may
not be readily available resulting in an unnecessary delay. These
drugs could also play a role in mass transportation settings like
cruises or group travel. The use of NIs does lead to reduction in
disease duration—if used within 48 h after first symptoms—about
1 day—and to reduction in disease severity, although this has been
also a matter of debate.46 In specific cases, such reductions may be
crucial: e.g. athletes, politicians, scientists and those travelling for
business.57 The prophylactic use of NI decreases the chance of be-
ing infected.57 To our knowledge, and in light of the recent
Olympics in Rio de Janeiro and upcoming sport events, NIs are
not currently listed as prohibited substances by the World Anti-
Doping Agency (WADA) [https://www.wada-ama.org/en/what-
we-do/prohibited-list (26 October 2016, date last accessed)].
The CDC currently suggests that patients infected with avian
influenza should be treated with oseltamivir or zanamivir.
Furthermore, the curative use of NIs is recommended as early as
possible, preferably within 48 h, for patients hospitalized with
confirmed or suspected influenza, with severe, complicated, or
progressive illness or at high risk for influenza-associated com-
plications (e.g. children<2years, adults 65years, nursing
home residents, individuals with major co-morbidities) accord-
ing to CDC guidelines (www.cdc.gov/flu/professionals/antivi
rals/summary-clinicians.htm). Currently, oseltamivir is FDA
registered for influenza treatment for any age and as chemopro-
phylaxis from 3 months of age. Age cut-offs for zanamivir use
are currently 7 and 5 years, respectively. Prophylactic dosing
with chloroquine—known to have some non-specific antiviral
efficacy in vitro—did not translate into clinical protection in a
large randomized controlled community trial during the H1N1
outbreak in 2009 and therefore does not seem to have a role in
travel medicine regarding influenza prevention.58
Vaccination of the Healthy, ‘Low Risk’ Traveller
Currently, seasonal influenza vaccination in most guidelines is
only advised for healthy travellers if they plan to attend large
events or to travel by cruise ship. This is mainly because influenza
is widely considered a relatively mild and self-limiting disease in
most healthy individuals.2 However, over the past decade, re-
ports of patients without co-morbidities who develop severe and
even lethal influenza with apparently ‘normal’ seasonal influenza
viruses, have steadily accumulated.7,32,36,37,59,60. Since seasonal
influenza is the most frequent vaccine preventable infectious dis-
ease in travellers, influenza vaccination should be part of regular
pre-travel advice for all travellers. This raises the more general
question about what burden of expected disease during the envis-
aged travel would justify inclusion of vaccination advice in travel
guidelines. The probability of acquiring influenza, severity of dis-
ease, expected effectiveness of the vaccine and cost are among the
factors that should be taken into account. One could argue that
the a priori chances of developing typhoid fever, hepatitis A or
tetanus during a two and half week trip to an Asian destination
are much lower than being infected with an influenza virus.
However, at least according to most guidelines issued in industri-
alized nations, these three immunizations are usually recom-
mended for most travellers going to many developing countries
while influenza vaccination is often not even considered.61
Vaccination of Travellers Belonging to High-Risk Groups
The majority of elderly individuals (60 or 65 years old) and
those with serious co-morbidities would be candidates for influ-
enza vaccination even without travel plans. However, it remains
important to assess vaccination status and to evaluate whether or
not the strains the individual has been vaccinated against are ap-
propriate for the geographic area and season of the travel plans
(see below). Recommendations for the elderly are not only based
on the inevitably growing number of co-morbidities in this age
group, but also on immune-senescence.62–64 Unfortunately, the
effectiveness of influenza vaccines is often impaired in individuals
who could benefit most from vaccination: immune-compromised
and elderly individuals, as well as patients in the other high-risk
groups mentioned in virtually all recommendations. Limited data
are available about the added value of recently introduced adju-
vanted, high-dose (HD) and quadrivalent vaccines (for review see
Reperant et al.65). To date, strong RCT data providing evidence
of superiority are only available for the HD formulation in the el-
derly and the effect was modest.66
Although in the past one has been reluctant to immunize
pregnant women, currently vaccination of pregnant women
against seasonal influenza is incorporated in most guidelines
and recommendations. This is based on the real risks of influ-
enza during pregnancy that by far outweighs the risks associated
with vaccination. During the H1N1 (2009) pandemic, influenza
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vaccines proved to be safe and effective for pregnant women
and their unborn babies; findings very similar to studies of sea-
sonal influenza vaccination in this high risk group.67,68 In line
with these recommendations, the advice might be broadened to
pregnant women travelling to influenza endemic areas and pos-
sibly to persons in close contact with pregnant women or other
high-risk individuals, like partners and close family members
[CDC guideline: http://www.cdc.gov/h1n1flu/clinician_preg
nant.htm (26 October 2016, date last accessed)] or travel
partners.
Influenza vaccination status of travellers in defined risk cate-
gories should be checked and either vaccination or additional
vaccination against influenza should be recommended on the ba-
sis of the epidemiological situation in the area of intended travel.
The relatively limited effectiveness of influenza vaccination in
most of the high-risk groups and the value of newer generations
of vaccines that might overcome these problems are important
topics for future study. Finally, for very frail patients, the advice
not to travel to certain areas should always be considered during
pre-travel consultation, although risk assessment in these cases
should obviously not be limited to the threat posed by influenza.
Mass Gatherings
The Hajj is undoubtedly among of the most challenging large-
scale events as regards infectious disease control. Every year
more than 10 million pilgrims from all over the world visit the
holy places of Islam in the Kingdom of Saudi Arabia. Almost
one-third of these pilgrims will perform this religious obligation
during a 6-day fixed period, called the Hajj. The remaining two-
thirds will perform the Umrah, which can be done at any time
in the year with peak incidence of visitors during Ramadan.69
The number of Hajj pilgrims has increased by a factor of 5 from
1920 to 201270 and, at specific pilgrimage ‘bottlenecks’, crowd-
ing can be as high as 3–4 persons/square meter.71 In a recent ex-
tensive review covering 31 Hajj-associated studies, respiratory
tract infections were by far the most common infections among
pilgrims with 60% of ill Hajjis presenting with respiratory tract
complaints.70 After rhinovirus, influenza viruses are the most
common cause of these respiratory complaints.72,73The rapid in-
crease in case numbers during the 6-day Hajj confirms the pre-
disposing conditions for influenza transmission during this
pilgrimage.73 Given the severe consequences that influenza can
have for high-risk groups and since influenza is currently the
only vaccine preventable respiratory virus infection in pilgrims,
the Ministry of Health of the Kingdom of Saudi Arabia recom-
mends that international pilgrims be vaccinated against seasonal
influenza with the most recently available vaccines.70,74,75 The
need to aim for optimal vaccination coverage of pilgrims during
the Hajj is further confirmed by studies showing that almost
50% of the pilgrims in the 2009 Hajj had at least one risk factor
for the development of severe influenza.76 Despite the Saudi
government requirement, a recent cross-sectional study showed
vaccination coverage in Malaysian pilgrims to be only 65.2%.77
Of course, non-pharmaceutical measures (e.g. hand hygiene,
wearing face masks and social distancing) could further reduce
influenza transmission during the Hajj, although effectiveness
outcomes have not always been convincing.78 However, com-
bined data from multiple studies suggest that the prevalence of
ILI has decreased among Hajj pilgrims as vaccine coverage
increased over the last decade.79 Influenza outbreaks are not re-
corded very often at other large-scale religious and sporting or
cultural events, but reported examples include the religious
World Youth Day in Sydney, Australia 2008, outbreaks at musi-
cal events in 2009 in Belgium, Hungary and Serbia, and at the
winter Olympics in Salt Lake City in 2002.59,60,80
Cruise Ship Holidays
Special attention should be given to the prevention and manage-
ment of influenza during cruise ship holiday travel. Some mod-
ern cruise ships carry over 5000 passengers served by more than
2000 crew-members,81 who may come from and, during the
cruise, may also visit several geographical areas or even travel
between the hemispheres. Often, at least some of the passengers
originate from a part of the world where there is an influenza
epidemic. Crews of these ships may function as reservoirs for in-
fluenza viruses between trips, since they often work long periods
throughout the season, while having contact with the changing
groups of passengers. In the last two decades, multiple reports
have described influenza outbreaks on cruise ships. Most were
seasonal influenza outbreaks, that occurred outside the ‘tradi-
tional’ influenza seasons characteristic of the temperate re-
gions.82,83 A recent systematic review of 41 studies of
respiratory virus propagation during transportation and in
transportation hubs found that cruise ship influenza outbreaks
typically affect 2–7% of the passengers.84 After acute gastroen-
teritis, influenza is the most common communicable ship-board
illness.85 In most cruise ship influenza outbreaks, crew members
are at the highest risk of infection, probably because their living
quarters are more crowded, facilitating spread.85 Although an
influenza outbreak can occur on any cruise worldwide, out-
breaks were most frequently reported from cruises travelling to
Alaska, Australia/Trans-Tasman and South America.86–98
Increased Influenza vaccination coverage of passengers and
crew would logically be expected to result in decreasing disease
burden. However, mismatches between circulating and vaccine
strains, in part based on differences between the vaccines for the
respective hemispheres, may reduce the effectiveness of this
strategy. Together with the reduced response of elderly and
immune-compromised individuals, the level of protection af-
forded by increased vaccination coverage may be insufficient to
prevent outbreaks89 and implementation of other prevention
strategies should be considered. In 2009, a previously estab-
lished European Union project (SHIPSAN) actively promoted
measures to prevent communicable disease outbreaks on passen-
ger ships, with special emphasis on the H1N1 influenza pan-
demic.90 There have been reports describing successful
interruption of influenza transmission on cruise ships through
the introduction of a combination of measures including surveil-
lance, isolation, and vaccination of crew, complemented with
antiviral chemoprophylaxis for both crew and passengers.81
Most likely due to the relatively slow speed of sea travel
compared with airplane travel, there are no indications to date
that sea transport accelerates global influenza spread.84
Avian Influenza and Travel Medicine
Although human cases of severe avian influenza virus infections
have been reported in Asia since 1997 when a highly pathogenic
(for poultry) avian influenza A H5N1 infection affected 18
Journal of Travel Medicine, 2016, Vol. 24, No. 1 5
people in Hongkong, 6 of whom died,91–93 there have not yet
been many reports of avian influenza in travellers. Recently, a
case report was published of an otherwise healthy Canadian 28-
year-old woman who returned from China with a fatal pneumo-
nia and meningoencephalitis due to highly pathogenic (for poul-
try) avian influenza A H5N1 infection.94 Another case report
described a 59-year-old woman who visited a poultry market in
South China as a tourist and developed dyspnea and haemopty-
sis due to severe pneumonia associated with a combined H5N1
and mycoplasma infection.95 Although the risk of acquiring
avian influenza is relatively low, such rare but frequently fatal
infections in travellers must be considered during pre-travel ad-
vice. A low pathogenic (for poultry) avian influenza H7N9 virus
has recently emerged in China and has infected hundreds of hu-
mans with a case fatality rate of about 20%.6,74 H7N9 cases im-
ported by travellers have been reported from numerous
countries outside China where poultry-to-human transmission
is continuing.6 So far, human-to-human transmission of these
avian influenza virus strains is rare, and therefore prevention
should focus predominantly on avoidance of traveller contact
with poultry and uncooked poultry products.
Preventive Measures and Treatment Options for Avian
Influenza
Although avian influenza only sporadically occurs in humans
with limited bird-to-human transmission, preventive measures
do play a role in dealing with traveller’s risk. Currently, no vac-
cines for avian influenza in humans are commercially available.
Therefore, prevention of infection with avian influenza viruses
should concentrate on raising awareness of travel medicine pro-
fessionals and adjusting traveller’s behaviour through pre-travel
advice. Particular attention should be given to travellers plan-
ning to visit areas endemic for avian influenza in poultry and
where human cases have occurred. Such areas are currently
found in Asia, Africa and the Middle East. Advice should focus
on avoiding contacts with patients suffering from respiratory
Table 1. Summary of available guidelines regarding influenza vaccination in travel medicine
Authority High-risk Normal risk Source
Australia Recommended Consider http://www.immunise.health.gov.au/internet/immunise/publishing.
nsf/Content/Handbook10-homehandbook10part3hand
book10-3-2 (26 October 2016, date last accessed)
Austria Government not mentioned not mentioned https://www.gesundheit.gv.at/Portal.Node/ghp/public/content/
Reiseimpfungen_LN.html (26 October 2016, date last accessed)
Austria Travel
Medicine
Recommended Recommended http://www.reisemed.at/krankheiten/influenza-echte-grippe
(26 October 2016, date last accessed)
France Recommended not mentioned http://www.invs.sante.fr/beh/2015/reco/pdf/2015_reco.pdf
Germany CRM Mentioned Mentioned https://www.crm.de/krankheiten/krankheiten.asp?
Domain¼CRM&Sprache¼de&Bereich¼krankheiten&Klientel
laie&Auspraegung¼kurz&HTMLfragmente¼no&Auswahl¼A-
Z (26 October 2016, date last accessed)
Germany DTG Recommended Useful http://www.dtg.org/influenzasaisonal.html (26 October 2016,
date last accessed)
Switzerland Recommended Not mentioned http://www.safetravel.ch/safetravel2/servlet/ch.ofac.wv.wv204j.
pages.Wv204ConseilsSanteListeCtrl?
action¼afficheDetail&elementCourant¼0 (26 October 2016,
date last accessed)
The Netherlands Recommended Not recommended http://www.mijnlcr.nl (26 October 2016, date last accessed)
United Kingdom Southern hemi-
sphere vaccine
not available.
Consult health-
care provider
for advice.
Not mentioned
(no influenza page
on NaTHNaC site)
http://travelhealthpro.org.uk/olympic-and-paralympic-games-
2016-brazil/ (26 October 2016, date last accessed)
Canada Not
recommended
Not recommended http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-10-eng.php (26
October 2016, date last accessed)
United States Recommended Recommended http://wwwnc.cdc.gov/travel/diseases/influenza-seasonal-zoonotic-
and-pandemic (26 October 2016, date last accessed)
World Health
Organization
Should be
vaccinated
not mentioned http://www.who.int/ith/vaccines/seasonal_influenza/en/
(26 October 2016, date last accessed)
Kingdom of
Saudi Arabia
Must be
vaccinateda
Should be vaccinateda http://www.moh.gov.sa/en/Hajj/Pages/HealthRegulations.aspx
(26 October 2016, date last accessed)
Brazil Refer to WHO
guidelines
Refer to WHO
guidelines
http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/
leia-mais-o-ministerio/440-secretaria-svs/viajante/viajante-en/
9654-brazilians-abroad (26 October 2016, date last accessed)
South Africa No travel
guidelinesb
No travel guidelinesb
aMinistry of health of Saudi Arabia have made influenza vaccination compulsory for Hajj and Umrah related visa applications.
bSouth African ministry of health recommend a yearly flu vaccine for everyone 6 months of age and older.
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disease, and contacts with birds and their excreta at live bird
markets or farms, as well as avoiding contacts with, and con-
sumption of insufficiently cooked poultry products. Since con-
sumption of poultry blood and uncooked poultry meat has been
associated with bird-to-human transmission, poultry products
for human consumption should be fully cooked, and should
therefore preferably not be purchased from street vendors.
Visits to live-bird markets in endemic areas should be discour-
aged, as aerosol transmission has been shown to be a risk factor
(i.e. contamination with aerosolized poultry faeces). General hy-
giene measures like washing and disinfecting hands may limit
avian influenza virus transmission6 but only limited data are
available about direct and indirect bird-to-human transmission
and prevention in travellers going to areas endemic for avian in-
fluenza in poultry. A questionnaire-based study among
Australian backpackers going to areas with outbreaks of avian
H5N1 virus in poultry suggests an overall poor knowledge of
this infection.96,97 While currently relying on such generic pre-
ventive measures, vaccine development efforts for H5N1 and
H7N9 viruses are on-going.81 This effort is not directed towards
the development of travel vaccines however, but rather for pan-
demic preparedness, since the avian viruses may cause a future
pandemic through mutation or re-assortment.3,4 In view of the
risk posed by avian influenza viruses, the early or, in specific
cases, even preventive use of antivirals like oseltamivir and pera-
mivir may be live saving. Since the availability of potent NIs
may be limited in some areas, travellers with a high likelihood
of exposure, like poultry workers, veterinarians or medical doc-
tors should consider bringing these drugs with them.
Pandemic Influenza and Travel Medicine
Data and recommendations summarized for seasonal influenza
and travel medicine also apply to an influenza pandemic. During
a pandemic however, guidelines and recommendations will be is-
sued by international and national health authorities largely based
on the knowledge available regarding the influenza strain as it
spreads. As we have also learned from the 2009 influenza pan-
demic, vaccination advice, antiviral use and target groups will
likely differ between pandemics and therefore tailor-made advice
should be provided. Strain-specific travel advice may also be ap-
propriate in this setting to reduce spreading of the pandemic virus
through air travel, in order to buy time for the development and
implementation of intervention and mitigating strategies.
Availability of Effective Influenza Vaccines — Action
Needed
WHO recommends that “high-risk individuals travelling from
one hemisphere to the other shortly before or during the other
hemisphere’s influenza season should obtain the vaccination rec-
ommended for the opposite hemisphere two weeks before trav-
el” [http://www.who.int/ith/vaccines/seasonal_influenza/en/ (26
October 2016, date last accessed)]. However, compliance with
this recommendation depends largely on availability of the ap-
propriate vaccine in the country of residence. Unfortunately,
even in years when the northern and southern hemisphere vac-
cines contain identical strains, the shelf life of the local ‘winter
influenza vaccine’ has typically expired when travel is considered
and neither the following winter season vaccine nor the opposite
hemisphere vaccine are available (i.e. licensed in the country of
departure). Thus, when no suitable influenza vaccine is available
locally, the traveller should arrange vaccination as soon as possi-
ble after arriving at the travel destination, bearing in mind that
vaccine-induced protection may take 1–2 weeks to develop.98
Furthermore, the likelihood of travellers on short-term holidays
seeking out influenza vaccination in the country they are visiting
is highly unlikely to happen. This approach may be particularly
important in years with a significant change in formulation be-
tween northern and southern hemisphere vaccines. In some
years, simply increasing the shelf-life of seasonal influenza vac-
cine would improve this situation. Commercial vaccines often
maintain acceptable potency for many months after they have
‘expired’. In addition, efforts should be made by pharmaceutical
industry and regulatory bodies to make opposite hemisphere in-
fluenza vaccines available at least for travel clinics. Obviously,
success in the development of more universal influenza vaccines
that would induce longer lasting and increased effectiveness
would bring great benefits for the combat of influenza not only
in high-risk groups but also for travellers.65,74
Future Studies
Given the impact and burden of disease caused by travel-related
influenza, the prevention and management of influenza before
and during travel is a field of travel medicine that disserves
more attention than it gets today. Current data show that vac-
cine coverage among travellers can be greatly improved.79,99–101
Future studies should focus on both a better understanding of
the epidemiological aspects of seasonal influenza and optimiza-
tion of vaccination strategies. Although the WHO advises trav-
ellers going to the opposite hemisphere to be vaccinated with a
vaccine containing strains circulating at their destination [http://
www.who.int/ith/ITH2010chapter6 (26 October 2016, date
last accessed)], this advice is currently almost impossible to im-
plement except by advising travellers to seek vaccination imme-
diately upon arrival at their destination. Increasing the shelf-life
of seasonal influenza vaccines could improve the situation in
years when the strains do not change between northern and
southern formulations but other strategies should also be pur-
sued, like ensuring global licensure of seasonal vaccines and de-
velopment of more universal vaccines. Improvement in the
effectiveness of seasonal influenza vaccines would especially
benefit the very young and old as well as the immune-
compromised since vaccine efficacy continues to be far from sat-
isfactory in these high-risk groups. Although only sporadic cases
of travel-related avian influenza have been reported to date,
these infections are usually severe and often fatal. In the absence
of registered vaccines for avian influenza and, in view of their
sporadic and geographically restricted nature, preventive mea-
sures should focus on adequate pre-travel advice to reduce expo-
sure. Finally, the availability of specific antivirals for early
treatment or prevention of seasonal and avian influenza in trav-
ellers needs to be given more attention and should be covered in
(inter)national guidelines.
Conclusions
Seasonal influenza is a significant problem for travellers that
should be routinely addressed in pre-travel counselling and in
the differential diagnosis of any returning traveller with fever.
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We have aimed to provide an overview of the available litera-
ture and guidelines. Potential limitations of this overview might
come from guidelines not available in English or accessible by
our search strategy. However, based the available literature we
believe prevention and management of influenza before and
during travel is a field of travel medicine that disserves more at-
tention than it gets today. Expert advice about preventive hy-
gienic and behavioural measures, vaccination and options for
antiviral treatment should become routine elements of pre-
travel counselling. Seasonal influenza vaccination should be
strongly recommended for people in high-risk groups such as
the elderly, and the immune compromised, for whom such pro-
tective measures are already part of standard advice for non-
travellers in most jurisdictions (Table 1). Routine immunization
should also be considered for the healthy travel partners of these
high-risk individuals. Many would also recommend influenza
vaccination for all cruise ship travellers and crew, as well as for
travellers going to major religious gatherings and other mass
gathering events.74 In addition, influenza immunization can be
considered in any international traveller wishing to reduce the
personal risk of being incapacitated by influenza during travel.
Besides vaccination against influenza, travellers can be informed
about other means to reduce the risk of influenza and its trans-
mission, such as implementing hygienic and behavioural mea-
sures and options for rapid antiviral treatment.
Conflict of interest: None declared.
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